Duration of hepatitis B immunity in low risk children receiving hepatitis B vaccinations from birth

Pediatric Infectious Disease Journal

Volumn 23, Issue 7, 2004, Pages 650-655

  Petersen, Kenneth M ^a   Bulkow, Lisa R ^a   McMahon, Brian J ^b   Zanis, Carolyn ^a   Getty, Marilyn ^a   Peters, Helen ^a   Parkinson, Alan J ^a  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^b Viral Hepatitis Program   (United States)

Author keywords

Booster dose; Hepatitis B vaccine; Low risk population; Protection duration

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; RECOMBINANT HEPATITIS B VACCINE;

ADOLESCENT; ANTIBODY TITER; ARTICLE; CHILD; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOLOGICAL MEMORY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REVACCINATION; VACCINATION; VIRUS IMMUNITY;

ALASKA; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION SCHEDULE; INFANT; INFANT, NEWBORN; LONGITUDINAL STUDIES; MALE; RISK FACTORS; TIME FACTORS;

EID: 3142686650     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000130952.96259.fd     Document Type: Article

References (24)

1. Lee W. Hepatitis B virus infection. N Engl J Med. 1997;337:1733-1745.
2. Shete PB, Daum RS. Real versus theoretical: assessing the risks and benefits of postponing the hepatitis B vaccine birth dose. Pediatrics. 2002;109:701-703.
3. CDC. Hepatitis B virus: a comprehensive strategy for limiting transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR. 1991;40(RR-13):1-25.
4. Lauderdale DS, Oram RJ, Goldstein KP, Daum RS. Hepatitis B vaccination among children in inner-city public housing, 1991-1997. JAMA. 1999;282:1725-1730.
5. Yusuf HR, Daniels D, Smith P, Coronado V, Rodewald L. Association between administration of hepatitis B vaccine at birth and completion of the hepatitis and 4:3:1:3 vaccine series. JAMA. 2000;284:978-983.
6. West DJ, Calandra GB. Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine. 1996;14:1019-1027.
7. Del Canho R, Grosheide PLM, Mazel JA, et al. Ten-year neonatal hepatitis B vaccination program, the Netherlands, 1982-1992: protective efficacy and long-term immunogenicity. Vaccine. 1997;15:1624-1630.
8. Resti M, Azzari C, Mannelli G, Rossi ME, Lionetti P, Vierucci A. Ten-year follow-up study of neonatal hepatitis B immunization: are booster injections indicated? Vaccine. 1997;15:1338-1340.
9. Huang LM, Chiang BL, Lee CY, Lee PI, Chi WK, Chang MH. Long-term response to hepatitis B vaccination and response to booster in children born to mothers with hepatitis B e antigen. Hepatology. 1999;29:954-959.
10. Yuen MF, Lim WL, Cheng CC, Lam SK, Lai CL. Twelve-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine versus plasma-derived vaccine without booster doses in children. Hepatology. 1999;29:924-927.
11. DaVilla G, Peluso F, Picciotto L, Bencivenga M, Elia S, Pelliccia MG. Persistence of anti-HBs in children vaccinated against viral hepatitis B in the first year of life: follow-up at 5 and 10 years. Vaccine. 1996;16:1503-1505.
12. DaVilla G, Pelliccia MG, Peluso F, Ricciardi E, Sepe A. Anti-HBs responses in children vaccinated with different schedules of either plasma-derived or HBV DNA recombinant vaccine. Res Virol. 1997;148:109-114.
13. Hollinger FB, Dreesman GR. Immunobiology of hepatitis viruses. In: Rose NR, Friedman H, Fahley L, eds. Manual of Clinical Laboratory Immunology. 3rd ed. Washington, DC: American Society for Microbiology; 1986:568.
14. Wainwright RB, McMahon BJ, Bulkow LR, et al. Duration of immunogenicity and efficacy of hepatitis B vaccine in a Yupik Eskimo population. JAMA. 1989;261:2362-2366.
15. Wainwright RB, Bulkow LR, Parkinson AJ, Zanis C, McMahon BJ. Protection provided by hepatitis B vaccine in a Yupik Eskimo population: results of a 10-year study. J Infect Dis. 1997;175:674-677.
16. Harpaz R, McMahon BJ, Margolis HS, et al. Elimination of new chronic hepatitis B virus infections: results of the Alaska immunization program. J Infect Dis. 2000;181:413-418.
17. Heijtink RA, van Bergen P, Paulij WP, de Man RA, Osterhaus AD. Anti-HBs characteristics after hepatitis B immunization with plasma-derived and recombinant DNA-derived vaccines. Vaccine. 2000;18:1531-1538.
18. West DJ, Watson B, Lichtman J, Hesley TM, Hedberg K. Persistence of immunologic memory for 12 years in children given hepatitis B vaccine in infancy. Pediatr Infect Dis J. 1994;13:745-747.
19. Faustini A, Franco E, Sangalli M, et al. Persistence of anti-HBs 5 years after the introduction of routine infant and adolescent vaccination in Italy. Vaccine. 2001;19:2812-2818.
20. Seto D, West DJ, Ioli V. Persistence of antibody and immunologic memory in children immunized with hepatitis B vaccine at birth. Pediatr Infect Dis J. 2002;21:793-795.
21. Bulkow LR, Wainwright RB, McMahon BJ, Parkinson AJ. Increases in levels of antibody to hepatitis B surface antigen in an immunized population. Clin Infect Dis. 1998;26:933-937.
22. Wu JS, Hwang LY, Goodman KJ, Beasley RP. Hepatitis B vaccination in high-risk infants: 10-year follow-up. J Infect Dis. 1999;179:1319-1325.
23. Lai CL, Wong BCY, Yeoh EK, Lim WL, Chang WK, Lin HJ. Five-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA year vaccine vs. plasma-derived vaccine in children: immunogenicity and anamnestic responses. Hepatology. 1993;18:763-767.
24. European Consensus Group on Hepatitis B Immunity. Are booster immunizations needed for lifelong hepatitis B immunity? Lancet. 2000;355:561-565.